Ten companies across mixed sectors also mirrored a broader market optimism, booking modest gains during the end of the ...

Research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Aldeyra Therapeutics in a ...

Equities researchers at HC Wainwright cut their Q1 2025 EPS estimates for shares of Soleno Therapeutics in a report released ...

H.C. Wainwright analyst initiates coverage on Surf Air Mobility Inc. with a Buy rating and $12 price target, citing potential ...

Fintel reports that on March 7, 2025, HC Wainwright & Co. initiated coverage of Surf Air Mobility (NYSE:SRFM) with a Buy ...

H.C. Wainwright lowered the firm’s price target on Repare Therapeutics (RPTX) to $5 from $10 and keeps a Buy rating on the shares following the ...

H.C. Wainwright lowered the firm’s price target on Gold Resource (GORO) to $1.25 from $1.75 and keeps a Buy rating on the shares after the ...

Fintel reports that on March 6, 2025, HC Wainwright & Co. initiated coverage of ImmunityBio (NasdaqGS:IBRX) with a Buy ...

Plug Power (Nasdaq: PLUG). From a high north of $3, shares of the hydrogen pioneer have been cut roughly in half, falling as ...

LAVA Therapeutics reviews strategic options amid cost cuts. HC Wainwright downgrades stock, citing uncertainties over LAVA-1266 and possible business shifts.

A live webcast and replay will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website at https://investors.in8bio.com. IN8bio is a clinical-stage ...